Bez kategorii

Is CBD the New E-Cig Scare? – Motley Fool

The Food and Drug Administration still refuses to acknowledge electronic cigarettes may be a healthier alternative to traditional cigarettes, even though much of the rest of the world actively promotes smokers switching to e-cigs as safer.

The agency used an outbreak of lung injuries and deaths this summer related to vaping to urge the public to stop using the devices altogether until it knows more about what caused the illnesses, even though it all but confirmed they were related to illicit e-liquids bought over the internet.

Scientist putting drops of oil in a bottle next to marijuana plants.

Image source: Getty Images.

Now the agency is using a similar tactic with cannabidiol, or CBD, the nonpsychotropic compound found in marijuana and hemp, reiterating that not only is it illegal to use CBD in food or to market it as a supplement, but that there are also just too many unknowns for people to safely use CBD.

The results of both of these actions were predictable: The companies invested in these products were crushed in the market. 

The future is still cloudy for CBD

The FDA admits there is „significant public interest” in cannabis and cannabis compounds like CBD, but it warns consumers not to be lulled into thinking they’re safe. The agency did approve GW Pharmaceutical‚s (NASDAQ:GWPH) Epilodex drug containing CBD to treat two rare illnesses. But even the pharmaceutical-grade compound in Epilodex exposed users to potential side effects including liver damage, reactions to other drugs, and harm to male reproductive function.

The potential ramifications of using over-the-counter formulations of CBD remain murky, especially if people are using it simultaneously across multiple applications, such as in edibles and in topical creams. The impact on certain populations like the elderly, children, or even lactating mothers is unknown.

It’s not exactly fear-mongering, especially since the FDA says it wants to use a science-based approach to approve products to market and the agency needs to be cautious when it comes to public health. It says it wants consumers to have the facts before using CBD products.

Yet the regulatory body hasn’t moved quickly in formulating a clear policy on CBD, all the while citing the risks associated with it, which results in the scales tipping toward opposition. And it could be years before official policy becomes more balanced.

Erecting hurdles to adoption

That’s not unlike the situation with e-cigs, which are generally recognized as a safer and healthier option for smokers. The FDA has yet to label any device as reduced-risk (but it did approve Swedish Match‚s brand of snus, which is a moist, powdered tobacco product).

Although the agency’s advisory panel recommended that the heat-not-burn e-cig from Philip Morris International (NYSE:PM) be approved for a reduced-risk label, the FDA has not acted on it for three years now, even though the application was submitted months before the marketing application.

Instead, the FDA has spent a lot of time taking the industry to task for a reported rise in teenage use of e-cigs and has targeted leading manufacturer Juul Labs for particular scrutiny. Altria (NYSE:MO) was forced to write down more than a quarter of the value of its $12.8 billion investment in the e-cig maker, which it was also excoriated for by investors. The agency has also proposed banning all flavored e-liquids, even though adults use flavors to help them transition away from smoking.

Never let a crisis go to waste

Rather than encourage smokers to make the switch to e-cigs, the FDA has made it clear that it views any nicotine use as harmful and has erected an expensive, labyrinthine approval process (so far, only two of the biggest tobacco giants have managed to submit applications for review). The deadline for the industry is May 2020, suggesting many won’t make it.

It also used the outbreak of lung illnesses to bolster its animus against the industry, even though not a single e-cig manufacturer has been implicated in the health scare. 

As a result, the growth in e-cig use has tumbled while the decline in cigarette smoking has eased, suggesting people have stopped using e-cigs and taken up smoking again. That can hardly be considered a policy win.

CBD and e-cigs remain in limbo

The recent policy clarification on CBD doesn’t seem much different. The FDA used the opportunity to highlight the risks and discuss how it’s cracking down on companies violating its rules, but didn’t offer any illumination on when a cohesive framework for regulation would be forthcoming. Since we already knew the FDA would lean against CBD use, much as it is against e-cigs, it makes it difficult for any pot producers wanting to offer CBD-infused products.

Investors in both CBD and e-cigs may want to proceed cautiously as the regulatory landscape remains uncertain because of the FDA.

Is CBD the New E-Cig Scare? – Nasdaq

The Food and Drug Administration still refuses to acknowledge electronic cigarettes may be a healthier alternative to traditional cigarettes, even though much of the rest of the world actively promotes smokers switching to e-cigs as safer.

The agency used an outbreak of lung injuries and deaths this summer related to vaping to urge the public to stop using the devices altogether until it knows more about what caused the illnesses, even though it all but confirmed they were related to illicit e-liquids bought over the internet.

Scientist putting drops of oil in a bottle next to marijuana plants.

Image source: Getty Images.

Now the agency is using a similar tactic with cannabidiol, or CBD, the nonpsychotropic compound found in marijuana and hemp, reiterating that not only is it illegal to use CBD in food or to market it as a supplement, but that there are also just too many unknowns for people to safely use CBD.

The results of both of these actions were predictable: The companies invested in these products were crushed in the market. 

The future is still cloudy for CBD

The FDA admits there is „significant public interest” in cannabis and cannabis compounds like CBD, but it warns consumers not to be lulled into thinking they’re safe. The agency did approve GW Pharmaceutical‚s (NASDAQ: GWPH) Epilodex drug containing CBD to treat two rare illnesses. But even the pharmaceutical-grade compound in Epilodex exposed users to potential side effects including liver damage, reactions to other drugs, and harm to male reproductive function.

The potential ramifications of using over-the-counter formulations of CBD remain murky, especially if people are using it simultaneously across multiple applications, such as in edibles and in topical creams. The impact on certain populations like the elderly, children, or even lactating mothers is unknown.

It’s not exactly fear-mongering, especially since the FDA says it wants to use a science-based approach to approve products to market and the agency needs to be cautious when it comes to public health. It says it wants consumers to have the facts before using CBD products.

Yet the regulatory body hasn’t moved quickly in formulating a clear policy on CBD, all the while citing the risks associated with it, which results in the scales tipping toward opposition. And it could be years before official policy becomes more balanced.

Erecting hurdles to adoption

That’s not unlike the situation with e-cigs, which are generally recognized as a safer and healthier option for smokers. The FDA has yet to label any device as reduced-risk (but it did approve Swedish Match‚s brand of snus, which is a moist, powdered tobacco product).

Although the agency’s advisory panel recommended that the heat-not-burn e-cig from Philip Morris International (NYSE: PM) be approved for a reduced-risk label, the FDA has not acted on it for three years now, even though the application was submitted months before the marketing application.

Instead, the FDA has spent a lot of time taking the industry to task for a reported rise in teenage use of e-cigs and has targeted leading manufacturer Juul Labs for particular scrutiny. Altria (NYSE: MO) was forced to write down more than a quarter of the value of its $12.8 billion investment in the e-cig maker, which it was also excoriated for by investors. The agency has also proposed banning all flavored e-liquids, even though adults use flavors to help them transition away from smoking.

Never let a crisis go to waste

Rather than encourage smokers to make the switch to e-cigs, the FDA has made it clear that it views any nicotine use as harmful and has erected an expensive, labyrinthine approval process (so far, only two of the biggest tobacco giants have managed to submit applications for review). The deadline for the industry is May 2020, suggesting many won’t make it.

It also used the outbreak of lung illnesses to bolster its animus against the industry, even though not a single e-cig manufacturer has been implicated in the health scare. 

As a result, the growth in e-cig use has tumbled while the decline in cigarette smoking has eased, suggesting people have stopped using e-cigs and taken up smoking again. That can hardly be considered a policy win.

CBD and e-cigs remain in limbo

The recent policy clarification on CBD doesn’t seem much different. The FDA used the opportunity to highlight the risks and discuss how it’s cracking down on companies violating its rules, but didn’t offer any illumination on when a cohesive framework for regulation would be forthcoming. Since we already knew the FDA would lean against CBD use, much as it is against e-cigs, it makes it difficult for any pot producers wanting to offer CBD-infused products.

Investors in both CBD and e-cigs may want to proceed cautiously as the regulatory landscape remains uncertain because of the FDA.

Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Simply click here to get the full story now.

Learn more

Rich Duprey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tenet Healthcare (THC) Is Up 10.34% in One Week: What You Should Know – Nasdaq


Warning: sprintf(): Too few arguments in /var/www/vaporizers.pl/wp-content/themes/blogito/inc/template-tags.php on line 319

Momentum investing revolves around the idea of following a stock’s recent trend in either direction. In the ‚long’ context, investors will be essentially be „buying high, but hoping to sell even higher.” With this methodology, taking advantage of trends in a stock’s price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Tenet Healthcare (THC), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It’s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Tenet Healthcare currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let’s discuss some of the components of the Momentum Style Score for THC that show why this hospital operator shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For THC, shares are up 10.34% over the past week while the Zacks Medical – Hospital industry is up 2.52% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 23.91% compares favorably with the industry’s 3.61% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics — such as performance over the past three months or year — can be useful as well. Over the past quarter, shares of Tenet Healthcare have risen 48.32%, and are up 58.81% in the last year. On the other hand, the S&P 500 has only moved 5.64% and 21%, respectively.

Investors should also pay attention to THC’s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. THC is currently averaging 1,017,886 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock’s price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with THC.

Over the past two months, 8 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost THC’s consensus estimate, increasing from $2.40 to $2.70 in the past 60 days. Looking at the next fiscal year, 6 estimates have moved upwards while there have been 3 downward revisions in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that THC is a #2 (Buy) stock with a Momentum Score of A. If you’ve been searching for a fresh pick that’s set to rise in the near-term, make sure to keep Tenet Healthcare on your short list.

Click to get this free report

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tenet Healthcare (THC) Is Up 10.34% in One Week: What You Should Know – Yahoo Finance


Warning: sprintf(): Too few arguments in /var/www/vaporizers.pl/wp-content/themes/blogito/inc/template-tags.php on line 319

Momentum investing revolves around the idea of following a stock’s recent trend in either direction. In the ‚long’ context, investors will be essentially be „buying high, but hoping to sell even higher.” With this methodology, taking advantage of trends in a stock’s price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

It’s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Tenet Healthcare currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Let’s discuss some of the components of the Momentum Style Score for THC that show why this hospital operator shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For THC, shares are up 10.34% over the past week while the Zacks Medical – Hospital industry is up 2.52% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 23.91% compares favorably with the industry’s 3.61% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics — such as performance over the past three months or year — can be useful as well. Over the past quarter, shares of Tenet Healthcare have risen 48.32%, and are up 58.81% in the last year. On the other hand, the S&P 500 has only moved 5.64% and 21%, respectively.

Investors should also pay attention to THC’s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. THC is currently averaging 1,017,886 shares for the last 20 days.

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock’s price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with THC.

Over the past two months, 8 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost THC’s consensus estimate, increasing from $2.40 to $2.70 in the past 60 days. Looking at the next fiscal year, 6 estimates have moved upwards while there have been 3 downward revisions in the same time period.

Taking into account all of these elements, it should come as no surprise that THC is a #2 (Buy) stock with a Momentum Score of A. If you’ve been searching for a fresh pick that’s set to rise in the near-term, make sure to keep Tenet Healthcare on your short list.

Click to get this free report
 
Tenet Healthcare Corporation (THC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research” data-reactid=”34″>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Tenet Healthcare Corporation (THC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

CBD beverage makers stake positions as category emerges – Campaign US

Some brands are touting flavors, others are highlighting a state of mind and several are putting the star ingredient, CBD, boldly on the center of the container. 

At the BevNET industry conference in Santa Monica, Calif., this week, CBD or hemp-derived beverages, were widely touted as the next big thing to hit the industry. New brands are proliferating, from grassroots start-ups to well-financed companies with experienced beverage-industry leadership. 

„It’s the Wild West,” says Gwendolyn Wyard, vice president of regulatory and technical affairs at the Organic Trade Association. 

Both camps are waiting for what will happen when the global beverage giants – Diageo, PepsiCo, The Coca-Cola Company, AB InBev – enter the market through their own development or brand acquisition. 

Speculation is that these companies, along with big box retailers like Target, Walmart and major grocery chains, are waiting until the FDA clarifies its regulatory approach for products containing the non-hallucogenic CBD or cannabidiol, commonly derived from the hemp plant.

„What am I doing today that will allow me to compete with Coke, Pepsi and AB-InBev?” asked Benjamin Witte, founder and CEO of New York City-based Recess, during a panel, The Race for Distinction in CBD.

Witte is positioning Recess CBD-spiked, flavored sparkling waters around how they make you feel. Cans feature a tagline, „Calm, Cool, Collected.” The website is prominently headlined, „We canned a feeling” one that is „not tired, not wired.”

Witte believes it’s the more abstract feelings that will draw consumers to CBD beverages rather than detailed ingredient breakdowns, such as milligrams of CBD. 

„Consumers don’t want to hear 50 facts about hemp. They want to know the feeling they’ll get,” said Witte. „It’s not the caffeine category; it’s the energy category.”

Mood33 hemp-infused herbal teas is another brand using feelings to get through to consumers. Mood33’s six mood formulations include joy, peace and passion. 

„Mood33 is essentially a tea brand with hemp as a hero,” said co-founder Eric Schnell, who was also a co-founder of the organic, bottled tea brand, Steaz. One of the most popular mood33 teas is the „joy” peach tea, a flavor that is popular with regular bottled brands.  

In addition to highlighting mood, mood33 distribution is focused on small chains and mom-and-pop stores in high density markets like New York City and Los Angeles, following the early footsteps of Snapple and Arizona teas. 

„There are too many sparkling herbals,” noted Schnell. „We are marketing gulp-able tea. We know the consumer in this category.”

The facts are key to Jonathan Eppers, the founder of Vybes. It’s somewhat medicinal looking label touts 25mg hemp CBD in each bottle. He started his company when he discovered how CBD helped him manage stress and anxiety. „CBD changed my life,” he said. „I consider it medicine.”

Vybes contains a higher dose than the 10 mg a bottle found in many CBD brands. „People are not going to spend $8 on a beverage just because it tastes good,” said Eppers. „We try to focus on the science in the bottle and the way it makes you feel.”

CBD-infused sparkling water, Daytrip Beverage Co., from San Francisco, is run by former executive at Rockstar Energy, Joey Cannata, who thinks that once the FDA makes clear its regulatory POV, „the floodgates will open.” 

„Right now the pond is pretty small, but it is there, with regional players where there’s less risk for them to do it” said Cannata. „No offense to Coke, Pepsi and Diageo, a lot of their growth over the years has come from mergers and acquisitions activity.”

California considers calling THC in pot a risk to moms-to-be – Santa Rosa Press Democrat

LOS ANGELES — More than three years after California voters broadly legalized marijuana, a state panel is considering if its potent, high-inducing chemical — THC — should be declared a risk to pregnant women and require warnings.

Studies have indicated that a rising number of mothers-to-be have turned to marijuana products for relief from morning sickness and headaches, though it’s effectiveness has not been backed by science.

Cannabis industry officials say too little sound research is available on THC to support such a move and warn that it could make marijuana companies a target for lawsuits with unverified claims of injuries from pot use during pregnancy.

“That seems like an open-ended checkbook. How do we defend ourselves?” said Los Angeles dispensary owner Jerred Kiloh, who heads the United Cannabis Business Association, an industry group.

Lawyers looking for a quick buck will say „give us $10,000 or we are going to take you into a long court case,” he added.

The California Cannabis Industry Association echoed that fear, noting that pot’s standing as an illegal drug at the federal level has choked off research by government agencies. Those studies are needed to determine if THC poses health risks for pregnant women.

“Good policy and consumer protections are based on facts and data,” spokesman Josh Drayton said.

The meeting Wednesday of the obscure state Developmental and Reproductive Toxicant Identification Committee in Sacramento will focus on whether THC causes “reproductive toxicity.” The panel is made up of scientists appointed by the governor.

An affirmative finding would make THC one of hundreds of chemicals judged to cause cancer or birth defects that the state requires to carry warning labels, such as arsenic and lead.

The review is being carried out under the umbrella of the Safe Drinking Water and Toxic Enforcement Act, better known as Proposition 65. It requires warning labels for chemicals judged as dangerous and allows residents, advocacy groups and attorneys to sue on behalf of the state and collect a portion of civil penalties for failure to provide warnings.

The 1986 law has been credited with weeding out cancer-causing chemicals from products but also faulted for setting the stage for legal shakedowns.

Since 2009, the state has listed marijuana smoke as being known to cause cancer, similar to tobacco smoke.

„The expansion of Proposition 65 as it relates to cannabis is premature and lacks both the facts and the data that would justify this move,” Drayton said.

The U.S. surgeon general warned in August that smoking marijuana is dangerous for pregnant women and their developing babies. Mainstream medicine advises against pot use in pregnancy because of studies suggesting it might cause premature birth, low birth weight or other health problems, but many of those studies were in animals or had findings that were open to dispute.

The National Institute on Drug Abuse is paying for several studies on marijuana use during pregnancy.

If the California panel declares pot a risk for pregnant women, it’s not clear what the immediate impact would be on the state’s legal pot industry.

Presumably, packaging would need to be changed over time to carry warning labels for pregnant women. But such requirements would likely take additional steps by agencies that oversee marijuana regulation and packaging.

Even products containing CBD, a trendy ingredient extracted from marijuana or hemp, can contain trace amounts of THC.

California Mulls Labeling THC a Risk During Pregnancy – Courthouse News Service

LOS ANGELES (AP) — More than three years after California voters broadly legalized marijuana, a state panel is considering whether its high-inducing chemical, THC, should be declared a risk to pregnant women and require warnings.

Studies have indicated that a rising number of mothers-to-be have turned to marijuana products for relief from morning sickness and headaches, though its effectiveness has not been scientifically proven.

Cannabis industry officials say too little sound research is available on THC to support such a move and warn that it could make marijuana companies a target for lawsuits with unverified claims of injuries from pot use during pregnancy.

Keira Sumimoto, of Irvine, Calif., used used marijuana briefly for medical reasons while pregnant and breastfeeding, and says her daughter is healthy and advanced for her age. (AP file photo)

“That seems like an open-ended checkbook. How do we defend ourselves?” asked Los Angeles dispensary owner Jerred Kiloh, who heads the United Cannabis Business Association.

Lawyers looking for a quick buck will say “give us $10,000 or we are going to take you into a long court case,” he said.

The California Cannabis Industry Association echoed that fear, noting that pot’s standing as an illegal drug at the federal level has choked off research by government agencies. Those studies are needed to determine if THC poses health risks for pregnant women.

“Good policy and consumer protections are based on facts and data,” spokesman Josh Drayton said.

The Wednesday meeting of the obscure state Developmental and Reproductive Toxicant Identification Committee in Sacramento will focus on whether THC causes “reproductive toxicity.” The panel is made up of scientists appointed by the governor.

An affirmative finding would make THC one of hundreds of chemicals judged to cause cancer or birth defects that the state requires to carry warning labels, such as arsenic and lead.

The review is being carried out under the umbrella of the Safe Drinking Water and Toxic Enforcement Act, better known as Proposition 65. It requires warning labels for chemicals judged as dangerous and allows residents, advocacy groups and attorneys to sue on behalf of the state and collect a portion of civil penalties for failure to provide warnings.

The 1986 law has been credited with weeding out carcinogenic chemicals from products but also faulted for setting the stage for legal shakedowns.

Since 2009, the state has listed marijuana smoke as carcinogenic, similar to tobacco smoke.

“The expansion of Proposition 65 as it relates to cannabis is premature and lacks both the facts and the data that would justify this move,” Drayton said.

The U.S. surgeon general warned in August that smoking marijuana is dangerous for pregnant women and their developing babies. Mainstream medicine advises against pot use in pregnancy because of studies suggesting it might cause premature birth, low birth weight or other health problems, but many of those studies were in animals or had findings that were open to dispute.

The National Institute on Drug Abuse is paying for several studies on marijuana use during pregnancy.

If the California panel declares pot a risk for pregnant women, it’s not clear what the immediate impact would be on the state’s legal marijuana industry.

Presumably, packaging would need to be changed over time to carry warning labels for pregnant women. But such requirements would likely take additional steps by agencies that oversee marijuana regulation and packaging.

Even products containing CBD, a trendy ingredient extracted from marijuana or hemp, can contain trace amounts of THC.

CBD boom becomes local – Greater Milwaukee Today


Rebecca Ramage, left, and Maureen Lawrenz stand inside Ramage’s Oconomowoc greenhouse before they moved their hemp plants to their Helenville farm in Jefferson County.
Submitted photo

OCONOMOWOC — The CBD boom across southeast Wisconsin has been well documented with dozens of CBD shops opening in the area over the last year.

But two Lake Country women have taken it upon themselves to start their own business, Lake Country Growers, where they take the plant from seed to harvest to CBD oil.

Owners Rebecca Ramage and her decade-long friend Maureen Lawrenz decided around this time last year that they would go ahead with “their crazy plan” and begin looking at how to make it a reality.

“We started in batches and worked up to size,” Ramage said. “It was about learning the process and perfecting it before we screwed it up on a giant scale.”

Once the process was done, Ramage — an Oconomowoc resident — and Lawrenz — a Watertown resident — ended up planting over 22,000 seeds that were eventually transplanted to their farm in Helenville in Jefferson County.

The transplant took place on Father’s Day this past spring and by the time October came around for harvest, the plants were eight feet tall.

In fact, Ramage said she and Lawrenz had to pick over 500 plants ahead of schedule because of the summer storm that brought a tornado along with it because their fields were oversaturated.

When it was all said and done, Ramage said, it was one of the happiest days of her life to have the hemp harvested.

“It was beautiful and sunny, we couldn’t have picked a better day,” she said.

The two had a grand opening launch of their business on Friday where they invited their families, friends and the community to come out and learn more about their business and their product.

“We feel very passionate about educating consumers as well instead of telling them to try this or try that,” Lawrenz said. “We want you to know what it is that is going into your body and why it isn’t marijuana.”

With a slew of CBD products on the market — any of which that be bought at a gas station, a movie store, a dispensary or at grocery stores — Lawrenz said it’s hard to find a producer that was with their product from seed to harvest.

“Oftentimes with producers of CBD, it’s very hard to find someone who grew it from the seed. We were part of the process the entire way through,” Lawrenz said. “We’re really proud of that and we feel the community can trust us with that.”

Ramage said she and Lawrenz always had the user in mind when treating their hemp.

“We used all organic practices, we didn’t use any chemicals, pesticides, herbicides or anything,” Ramage said. ‚We hand-weeded and we didn’t cut any corners, even though it was labor intensive.

“We did it because that’s what gave us the best quality product.”

Lake Country Growers debuted their 11 products including lotions, creams and tinctures, all of which can be found at www.lakecountrygrowers.com. For more information, visit their website or follow them on Facebook or Instagram.

HempAmericana Readies Launch of Online Payment Processing System Following Positive CBD Lab Results – GlobeNewswire

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE – HempAmericana, Inc. (OTC: HMPQ) (“HempAmericana” or the “Company”), an emerging leader in the CBD products market, is excited to announce that the Company is set to launch its online payment processing engine following positive results from the full-spectrum CBD product formula testing recently completed by EVIO Labs (“EVIO”), a best-in-class product testing and accreditation lab located in Berkeley, CA. These results, all of which confirm that HempAmericana’s products meet the legal limit for sale in the US and abroad, remove all remaining barriers, allowing the Company to begin processing online payments for CBD purchases through its new ecommerce sales portal. “We aren’t surprised by these test results from EVIO, and we are excited to begin taking online payments and providing our customers with the most convenient path to accessing our best-in-class CBD-based products,” commented Salvador Rosillo, CEO of HempAmericana. “EVIO is the best in the business. Every step of the way, we have opted to place quality ahead of convenience or expediency. And we will continue to conduct this business by the light of that North Star.” EVIO Labs has full-service testing facilities that allow testing for up to 17 cannabinoids, 66 pesticides, solvents, metals, microbial impurities, terpenes, water activity, moisture content, foreign material, and more. In addition, EVIO uses ultra-high performance liquid chromatography. The Company recently sent seven (7) full-spectrum CBD product formulas for analysis to EVIO, including samples ranging from 125mg to 2500mg in potency. All samples were tested and received positive results, and the Company is now in full compliance with US and international regulatory standards for online payment processing of CBD products. Rosillo continued, “With this simple step, HempAmericana is now past the final barrier to fully monetizing our tremendous potential. We have held ourselves to a higher standard. And we strongly believe that strategy is set to pay off for our shareholders. The CBD market continues to track toward accelerating growth to close out the year and in 2020. We have a strong inventory of premium quality products, and now we have no obstacles in the way of aggressive distribution.” About HempAmericana, Inc.
HempAmericana is an emerging leader in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. See more at www.hempamericana.com. 
Safe Harbor Provision. Cautionary statement for purposes of the „Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. Please also review Hemp Americana annual and quarterly financials for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state. Corporate Contact:
HempAmericana.com
Salvador Rosillo
HempAmericana, Inc.
Phone: (888) 977-7985
Press & Media Inquiries:
EHC Branding Agency
Info@EHCBrandingAgency.Com
(626) MJ-BRAND